T. Rowe Price Associates
BCAX

T. Rowe Price Associates’s Bicara Therapeutics BCAX Stock Holding History

T. Rowe Price Associates’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.4M Sell
1,376,198
-183,337
-12% -$3.16M ﹤0.01% 956
2025
Q4 		$26.2M Sell
1,559,535
-195,876
-11% -$3.35M ﹤0.01% 999
2025
Q3 		$27.7M Sell
1,755,411
-394,899
-18% -$4.42M ﹤0.01% 975
2025
Q2 		$20M Buy
2,150,310
+352,289
+20% +$4.2M ﹤0.01% 958
2025
Q1 		$23.4M Buy
1,798,021
+250,841
+16% +$3.33M ﹤0.01% 917
2024
Q4 		$27M Buy
1,547,180
+8,246
+0.5% +$172K ﹤0.01% 923
2024
Q3 		$39.2M Buy
+1,538,934
New +$39.2M ﹤0.01% 817

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

T. Rowe Price Associates's BCAX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Bicara Therapeutics (BCAX) stake by 12% in Q1 2026, selling an estimated $3.16M and leaving 1,376,198 shares worth $27.4M. The position accounts for ﹤0.01% of the portfolio, ranked #956.

T. Rowe Price Associates first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $39.2M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • T. Rowe Price Associates held 1,376,198 shares of Bicara Therapeutics worth $27.4M as of Q1 2026.
  • T. Rowe Price Associates sold 183,337 Bicara Therapeutics shares in Q1 2026, an estimated $3.16M.
  • Bicara Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #956 holding.
  • T. Rowe Price Associates first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • T. Rowe Price Associates's Bicara Therapeutics position peaked at $39.2M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.